4.7 Meeting Abstract

SAFETY AND EFFICACY OF LY3015014, A NEW MONOCLONAL ANTIBODY TO PROPROTEIN CONVERTASE SUBTILISIN/KEXIN TYPE 9 (PCSK9) WITH AN INHERENTLY LONGER DURATION OF ACTION, IN PATIENTS WITH PRIMARY HYPERCHOLESTEROLEMIA: A RANDOMIZED, PLACEBO-CONTROLLED, DOSE-RANGING, PHASE 2 STUDY

Journal

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY
Volume 65, Issue 10, Pages A1591-A1591

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/S0735-1097(15)61591-1

Keywords

-

Ask authors/readers for more resources

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available